
Dyne Therapeutics fell 17.5% from $20.24 to $16.70, behind the S&P 500's +11.2%. Its worst day was Dec 9 (−16.9%), and its low came Oct 16 at $14.25.
Nov 17, 2025 – Nov 16, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Dyne Therapeutics shares fell 16.9%, while the S&P 500 fell 0.1%.
−16.9%, the year's worst day · S&P 500 −0.1%
Story events cover the past 12 months · Times ET
EPS of $-0.76 missed the $-0.75 estimate on $0.00 revenue.
+3.4% · S&P 500 +0.1%
Dyne Therapeutics shares rose 11.8%, while the S&P 500 fell 0.2%.
+11.8% · S&P 500 −0.2%
EPS of $-0.73 beat the $-0.77 estimate on $0.00 revenue.
+4.8% · S&P 500 +0.2%
- 72-week trial will enroll approximately 90 participants; first site now open for enrollment -- Primary endpoint is rise from floor (RFF) velocity with multiple secondary endpoints to assess muscle and pulmonary
+10.3% · S&P 500 +1.0%
EPS of $-1.08 missed the $-0.75 estimate on $0.00 revenue.
+2.5% · S&P 500 +1.7%
Dyne Therapeutics closed at its highest level of the year, 32.3% above where the year started.
+3.0% · S&P 500 +0.2%
Dyne Therapeutics shares fell 16.4%, while the S&P 500 fell 0.5%.
−16.4%, on 17M shares, the year's heaviest volume · S&P 500 −0.5%
Dyne Therapeutics closed at its lowest level of the year, 29.6% below where the year started.
−6.8% · S&P 500 −1.1%
EPS of $-1.06 missed the $-0.88 estimate on $0.00 revenue.
−6.4% · S&P 500 −4.4%
Where it ended: a close of $16.70 on Nov 16, 2026. Up next: Q4 2026 earnings on Mar 1, 2027 (EPS est. $-1.00).
Nothing in the past 12 months.
All DYN dividend historyReplay the year: the line draws itself and stops at each of the 10 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for DYN and SPY from Benzinga historical bars. Not investment advice.